TY - JOUR
T1 - Physiological proteomics of heart failure
AU - O'Reilly, James
AU - Lindsey, Merry L.
AU - Baugh, John A.
N1 - Funding Information:
We acknowledge funding from the Health Research Board of Ireland ( CSA2012/36 ) and the National Institutes of Health under Award Numbers GM104357 , GM114833 , and GM115428 , HL051971 , HL075360 , HL129823 , and from the Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development under Award Number 5I01BX000505 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Veterans Administration.
Publisher Copyright:
© 2017
PY - 2018/2
Y1 - 2018/2
N2 - Heart failure (HF) is a complex clinical syndrome that is predominantly the result of coronary artery disease and hypertension. Despite advances in the treatment of myocardial infarction and HF, mortality has remained unchanged for several decades with approximately 50% of patients dying within five years of HF diagnosis. Recent statistics project a 46% increase in the incidence of HF by 2030, largely due to increases in the aging population and the prevalence of metabolic disorders such as obesity and diabetes. To develop diagnostic and prognostic biomarkers and effective therapies for the prevention, diagnosis, and treatment of HF, it is crucial that we improve our understanding of the complex pathophysiology of this disease. Advances in proteomic techniques are providing a means to map disease-specific alterations in the expression, location, and post-translational modification of proteins at the level of whole tissues, primary cells, and the extracellular matrix. The objective of this review is to summarize the evolving proteomics techniques and discuss recent data that has successfully used proteomic analysis to reveal new biomarkers, map functional networks that may drive disease progression, and identify potential therapeutic targets for HF.
AB - Heart failure (HF) is a complex clinical syndrome that is predominantly the result of coronary artery disease and hypertension. Despite advances in the treatment of myocardial infarction and HF, mortality has remained unchanged for several decades with approximately 50% of patients dying within five years of HF diagnosis. Recent statistics project a 46% increase in the incidence of HF by 2030, largely due to increases in the aging population and the prevalence of metabolic disorders such as obesity and diabetes. To develop diagnostic and prognostic biomarkers and effective therapies for the prevention, diagnosis, and treatment of HF, it is crucial that we improve our understanding of the complex pathophysiology of this disease. Advances in proteomic techniques are providing a means to map disease-specific alterations in the expression, location, and post-translational modification of proteins at the level of whole tissues, primary cells, and the extracellular matrix. The objective of this review is to summarize the evolving proteomics techniques and discuss recent data that has successfully used proteomic analysis to reveal new biomarkers, map functional networks that may drive disease progression, and identify potential therapeutic targets for HF.
UR - http://www.scopus.com/inward/record.url?scp=85051009179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051009179&partnerID=8YFLogxK
U2 - 10.1016/j.cophys.2017.12.010
DO - 10.1016/j.cophys.2017.12.010
M3 - Review article
AN - SCOPUS:85051009179
VL - 1
SP - 185
EP - 197
JO - Current Opinion in Physiology
JF - Current Opinion in Physiology
SN - 2468-8681
ER -